| NCT04173494 |
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) |
https://ClinicalTrials.gov/show/NCT04173494 |
Recruiting |
Sierra Oncology, Inc. |
2021-12-31 |
| NCT04097821 |
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients |
https://ClinicalTrials.gov/show/NCT04097821 |
Recruiting |
Novartis |
2024-01-16 |
| NCT03912064 |
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT |
https://ClinicalTrials.gov/show/NCT03912064 |
Recruiting |
Dana-Farber Cancer Institute |
2022-04-26 |
| NCT03402399 |
Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03402399 |
Recruiting |
Assaf-Harofeh Medical Center |
2019-12-09 |
| NCT03373877 |
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03373877 |
Active, not recruiting |
Samus Therapeutics, Inc. |
2020-10-31 |
| NCT03333187 |
Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability |
https://ClinicalTrials.gov/show/NCT03333187 |
Recruiting |
Universitätsklinikum Hamburg-Eppendorf |
2021-03-31 |
| NCT03326310 |
Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia |
https://ClinicalTrials.gov/show/NCT03326310 |
Recruiting |
University of Chicago |
2021-09-04 |
| NCT03194542 |
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence |
https://ClinicalTrials.gov/show/NCT03194542 |
Recruiting |
Celgene |
2021-06-16 |
| NCT03144687 |
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03144687 |
Active, not recruiting |
Incyte Corporation |
2020-07-31 |
| NCT03136185 |
IMG-7289 in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03136185 |
Recruiting |
Imago BioSciences,Inc. |
2020-12-31 |
| NCT03118492 |
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03118492 |
Recruiting |
City of Hope Medical Center |
2021-05-24 |
| NCT03116542 |
18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT03116542 |
Recruiting |
Hamad Medical Corporation |
2020-05-31 |
| NCT03069326 |
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03069326 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-02-28 |
| NCT03065400 |
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT03065400 |
Completed |
Icahn School of Medicine at Mount Sinai |
2020-05-28 |
| NCT03018223 |
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT |
https://ClinicalTrials.gov/show/NCT03018223 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2018-12-15 |
| NCT02966353 |
Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. |
https://ClinicalTrials.gov/show/NCT02966353 |
Completed |
Novartis |
2018-07-24 |
| NCT02917096 |
Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02917096 |
Active, not recruiting |
City of Hope Medical Center |
2020-10-05 |
| NCT02807077 |
PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects |
https://ClinicalTrials.gov/show/NCT02807077 |
Completed |
CTI BioPharma |
2015-07-31 |
| NCT02806375 |
PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02806375 |
Completed |
St. Petersburg State Pavlov Medical University |
2018-12-31 |
| NCT02784496 |
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02784496 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2024-09-30 |
| NCT02765724 |
Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects |
https://ClinicalTrials.gov/show/NCT02765724 |
Completed |
CTI BioPharma |
2015-06-30 |
| NCT02742324 |
Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg |
https://ClinicalTrials.gov/show/NCT02742324 |
Recruiting |
French Innovative Leukemia Organisation |
2020-12-31 |
| NCT02730884 |
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia |
https://ClinicalTrials.gov/show/NCT02730884 |
Completed |
M.D. Anderson Cancer Center |
2019-08-22 |
| NCT02718300 |
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02718300 |
Recruiting |
Incyte Corporation |
2021-01-31 |
| NCT02660281 |
URMC Related Haplo-identical Donor BMT |
https://ClinicalTrials.gov/show/NCT02660281 |
Recruiting |
University of Rochester |
2025-10-31 |
| NCT02593760 |
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) |
https://ClinicalTrials.gov/show/NCT02593760 |
Completed |
Hoffmann-La Roche |
2017-03-29 |
| NCT03165734 |
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03165734 |
Recruiting |
CTI BioPharma |
2022-07-31 |
| NCT01433445 |
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis |
https://ClinicalTrials.gov/show/NCT01433445 |
Completed |
Novartis |
2020-06-22 |
| NCT02515630 |
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
https://ClinicalTrials.gov/show/NCT02515630 |
Completed |
Sierra Oncology, Inc. |
2017-07-18 |
| NCT02493530 |
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea |
https://ClinicalTrials.gov/show/NCT02493530 |
Active, not recruiting |
Vanderbilt-Ingram Cancer Center |
2020-12-31 |
| NCT02436135 |
Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease |
https://ClinicalTrials.gov/show/NCT02436135 |
Completed |
Gilead Sciences |
2017-11-20 |
| NCT02426086 |
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor |
https://ClinicalTrials.gov/show/NCT02426086 |
Completed |
Geron Corporation |
2018-04-26 |
| NCT02386800 |
CINC424A2X01B Rollover Protocol |
https://ClinicalTrials.gov/show/NCT02386800 |
Recruiting |
Novartis |
2025-09-17 |
| NCT02370706 |
Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02370706 |
Active, not recruiting |
Novartis |
2020-09-02 |
| NCT02370329 |
P1101 in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02370329 |
Recruiting |
Mayo Clinic |
2020-03-31 |
| NCT03386214 |
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03386214 |
Recruiting |
Washington University School of Medicine |
2021-05-31 |
| NCT02311569 |
Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation |
https://ClinicalTrials.gov/show/NCT02311569 |
Completed |
Swiss Group for Clinical Cancer Research |
2016-12-31 |
| NCT02268253 |
Tagraxofusp (SL-401) in Patients With CMML or MF |
https://ClinicalTrials.gov/show/NCT02268253 |
Recruiting |
Stemline Therapeutics, Inc. |
2021-07-31 |
| NCT02267278 |
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF) |
https://ClinicalTrials.gov/show/NCT02267278 |
Completed |
M.D. Anderson Cancer Center |
2018-06-01 |
| NCT02251821 |
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02251821 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2021-03-11 |
| NCT02167958 |
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source |
https://ClinicalTrials.gov/show/NCT02167958 |
Completed |
University of Pittsburgh |
2019-09-21 |
| NCT02158858 |
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02158858 |
Recruiting |
Constellation Pharmaceuticals |
2021-08-31 |
| NCT02129101 |
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies |
https://ClinicalTrials.gov/show/NCT02129101 |
Completed |
Mayo Clinic |
2016-12-31 |
| NCT02124746 |
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT02124746 |
Completed |
Sierra Oncology, Inc. |
2018-12-06 |
| NCT02101268 |
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF |
https://ClinicalTrials.gov/show/NCT02101268 |
Completed |
Sierra Oncology, Inc. |
2016-07-28 |
| NCT02098161 |
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02098161 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-12-31 |
| NCT02087059 |
A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02087059 |
Completed |
Novartis |
2015-03-31 |
| NCT02065154 |
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis |
https://ClinicalTrials.gov/show/NCT02065154 |
Active, not recruiting |
University of Alabama at Birmingham |
2020-04-30 |
| NCT01317875 |
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) |
https://ClinicalTrials.gov/show/NCT01317875 |
Active, not recruiting |
Incyte Corporation |
2020-09-30 |
| NCT01290302 |
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01290302 |
Completed |
American Regent, Inc. |
2012-12-31 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT01369498 |
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01369498 |
Completed |
Gilead Sciences |
2014-06-05 |
| NCT01981850 |
A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01981850 |
Active, not recruiting |
Promedior, Inc. |
2017-08-30 |
| NCT01969838 |
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01969838 |
Completed |
Sierra Oncology, Inc. |
2016-09-12 |
| NCT01962636 |
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases |
https://ClinicalTrials.gov/show/NCT01962636 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-10-31 |
| NCT01814475 |
Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01814475 |
Completed |
Gruppo Italiano Trapianto di Midollo Osseo |
2016-12-31 |
| NCT01795677 |
JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01795677 |
Active, not recruiting |
French Innovative Leukemia Organisation |
2018-05-31 |
| NCT01787552 |
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF |
https://ClinicalTrials.gov/show/NCT01787552 |
Completed |
Novartis |
2018-04-10 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01732445 |
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01732445 |
Completed |
Mayo Clinic |
2016-07-14 |
| NCT01731951 |
Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01731951 |
Completed |
Geron Corporation |
2018-05-24 |
| NCT01712308 |
Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia |
https://ClinicalTrials.gov/show/NCT01712308 |
Recruiting |
M.D. Anderson Cancer Center |
2020-02-28 |
| NCT01693601 |
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) |
https://ClinicalTrials.gov/show/NCT01693601 |
Completed |
Icahn School of Medicine at Mount Sinai |
2018-05-18 |
| NCT01692366 |
Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly |
https://ClinicalTrials.gov/show/NCT01692366 |
Completed |
Sanofi |
2014-03-31 |
| NCT01644110 |
Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF |
https://ClinicalTrials.gov/show/NCT01644110 |
Recruiting |
University of Ulm |
2022-05-31 |
| NCT01633372 |
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01633372 |
Active, not recruiting |
Incyte Corporation |
2013-12-31 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01558739 |
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) |
https://ClinicalTrials.gov/show/NCT01558739 |
Completed |
Novartis |
2014-01-31 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01523171 |
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib |
https://ClinicalTrials.gov/show/NCT01523171 |
Completed |
Sanofi |
2014-04-30 |
| NCT01499147 |
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01499147 |
Completed |
University of Illinois at Chicago |
2013-05-31 |
| NCT01493414 |
INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. |
https://ClinicalTrials.gov/show/NCT01493414 |
Completed |
Novartis |
2017-01-26 |
| NCT01484015 |
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT01484015 |
Completed |
Wake Forest University Health Sciences |
2012-06-30 |
| NCT01445769 |
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01445769 |
Completed |
Incyte Corporation |
2013-03-31 |
| NCT01437787 |
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01437787 |
Completed |
Sanofi |
2014-06-30 |
| NCT01428635 |
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy |
https://ClinicalTrials.gov/show/NCT01428635 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-01-31 |
| NCT01423851 |
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF |
https://ClinicalTrials.gov/show/NCT01423851 |
Active, not recruiting |
NS Pharma, Inc. |
2020-11-30 |
| NCT01420770 |
Phase 2 Study of SAR302503 in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01420770 |
Completed |
Sanofi |
2014-04-30 |
| NCT01398462 |
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients |
https://ClinicalTrials.gov/show/NCT01398462 |
Completed |
JW Pharmaceutical |
2015-12-31 |
| NCT01392443 |
Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF |
https://ClinicalTrials.gov/show/NCT01392443 |
Completed |
Novartis |
2017-10-31 |
| NCT01387763 |
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms |
https://ClinicalTrials.gov/show/NCT01387763 |
Active, not recruiting |
Odense University Hospital |
2020-01-31 |
| NCT01384513 |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01384513 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT01375140 |
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01375140 |
Completed |
M.D. Anderson Cancer Center |
2018-09-05 |
| NCT01371617 |
A Phase 2 Study With IPI-926 in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01371617 |
Completed |
Infinity Pharmaceuticals, Inc. |
2012-08-31 |
| NCT01348490 |
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) |
https://ClinicalTrials.gov/show/NCT01348490 |
Completed |
Incyte Corporation |
2018-12-19 |
| NCT01340651 |
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients |
https://ClinicalTrials.gov/show/NCT01340651 |
Completed |
Incyte Corporation |
2012-07-31 |
| NCT03878524 |
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
https://ClinicalTrials.gov/show/NCT03878524 |
Recruiting |
OHSU Knight Cancer Institute |
2022-02-27 |
| NCT04282187 |
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT04282187 |
Recruiting |
University of Washington |
2024-11-11 |
| NCT04217993 |
Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis |
https://ClinicalTrials.gov/show/NCT04217993 |
Recruiting |
Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
2021-04-18 |
| NCT04176198 |
A Study of Oral TP-3654 in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT04176198 |
Recruiting |
Boston Biomedical, Inc |
2022-03-31 |
| NCT04064060 |
A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials |
https://ClinicalTrials.gov/show/NCT04064060 |
Recruiting |
Celgene |
2028-01-24 |
| NCT03952039 |
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib |
https://ClinicalTrials.gov/show/NCT03952039 |
Recruiting |
Celgene |
2021-11-24 |
| NCT03895112 |
MPN-RC 118 AVID200 in Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03895112 |
Recruiting |
Icahn School of Medicine at Mount Sinai |
2021-03-31 |
| NCT03886415 |
Jaktinib Dihydrochloride Monohydrate in Intermediate-risk and High-risk Myelofibrosis. |
https://ClinicalTrials.gov/show/NCT03886415 |
Recruiting |
Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
2021-02-01 |
| NCT03869476 |
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. |
https://ClinicalTrials.gov/show/NCT03869476 |
Recruiting |
University Hospital, Angers |
2023-06-30 |
| NCT03862157 |
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT03862157 |
Recruiting |
M.D. Anderson Cancer Center |
2024-01-01 |
| NCT03755518 |
An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib |
https://ClinicalTrials.gov/show/NCT03755518 |
Recruiting |
Celgene |
2022-05-19 |
| NCT03662126 |
KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor |
https://ClinicalTrials.gov/show/NCT03662126 |
Recruiting |
Kartos Therapeutics, Inc. |
2021-08-01 |
| NCT03645824 |
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) |
https://ClinicalTrials.gov/show/NCT03645824 |
Recruiting |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2022-09-30 |
| NCT03627403 |
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors |
https://ClinicalTrials.gov/show/NCT03627403 |
Recruiting |
University of Utah |
2024-03-14 |
| NCT03566446 |
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT03566446 |
Active, not recruiting |
Herlev Hospital |
2020-02-20 |
| NCT03441113 |
Extended Access of Momelotinib in Adults With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03441113 |
Enrolling by invitation |
Sierra Oncology, Inc. |
2024-12-31 |
| NCT03427866 |
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. |
https://ClinicalTrials.gov/show/NCT03427866 |
Recruiting |
Massachusetts General Hospital |
2021-09-30 |
| NCT03426969 |
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03426969 |
Recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT01236638 |
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) |
https://ClinicalTrials.gov/show/NCT01236638 |
Completed |
Sierra Oncology, Inc. |
2014-06-30 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01200498 |
Study of SB939 in Subjects With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01200498 |
Completed |
M.D. Anderson Cancer Center |
2012-11-30 |
| NCT01178281 |
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence |
https://ClinicalTrials.gov/show/NCT01178281 |
Completed |
Celgene |
2013-01-01 |
| NCT01149681 |
Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01149681 |
Completed |
PharmaMar |
2011-02-28 |
| NCT01134120 |
A Study in Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT01134120 |
Completed |
Eli Lilly and Company |
2014-04-30 |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT00997386 |
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States |
https://ClinicalTrials.gov/show/NCT00997386 |
Completed |
University of Arizona |
2014-04-30 |
| NCT00952289 |
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial |
https://ClinicalTrials.gov/show/NCT00952289 |
Completed |
Incyte Corporation |
2010-11-30 |
| NCT00946270 |
Pomalidomide for Myelofibrosis Patients |
https://ClinicalTrials.gov/show/NCT00946270 |
Completed |
M.D. Anderson Cancer Center |
2018-05-22 |
| NCT00935987 |
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) |
https://ClinicalTrials.gov/show/NCT00935987 |
Completed |
Sierra Oncology, Inc. |
2012-04-30 |
| NCT00934544 |
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial |
https://ClinicalTrials.gov/show/NCT00934544 |
Completed |
Novartis |
2015-03-04 |
| NCT00931762 |
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00931762 |
Completed |
Novartis |
2011-08-31 |
| NCT00910728 |
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases |
https://ClinicalTrials.gov/show/NCT00910728 |
Completed |
AstraZeneca |
2012-03-31 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT01423058 |
Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01423058 |
Completed |
Sierra Oncology, Inc. |
2014-06-30 |
| NCT00807677 |
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00807677 |
Completed |
Millennium Pharmaceuticals, Inc. |
2012-09-30 |
| NCT01787487 |
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm |
https://ClinicalTrials.gov/show/NCT01787487 |
Recruiting |
M.D. Anderson Cancer Center |
2020-07-26 |
| NCT03935555 |
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib |
https://ClinicalTrials.gov/show/NCT03935555 |
Recruiting |
Samus Therapeutics, Inc. |
2020-05-15 |
| NCT03222609 |
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03222609 |
Recruiting |
AbbVie |
2021-05-17 |
| NCT00745550 |
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00745550 |
Completed |
S*BIO |
2012-01-31 |
| NCT00724334 |
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00724334 |
Completed |
Sanofi |
2014-05-31 |
| NCT00719836 |
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies |
https://ClinicalTrials.gov/show/NCT00719836 |
Completed |
S*BIO |
2012-01-31 |
| NCT00669578 |
CC-4047 in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00669578 |
Completed |
Mayo Clinic |
2010-07-07 |
| NCT00631462 |
A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00631462 |
Completed |
TargeGen |
2009-10-31 |
| NCT00611351 |
Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00611351 |
Completed |
University of Nebraska |
2008-02-29 |
| NCT00606437 |
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants |
https://ClinicalTrials.gov/show/NCT00606437 |
Completed |
Duke University |
2014-02-28 |
| NCT00599547 |
Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients |
https://ClinicalTrials.gov/show/NCT00599547 |
Completed |
Universitätsklinikum Hamburg-Eppendorf |
2009-08-31 |
| NCT00589563 |
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer |
https://ClinicalTrials.gov/show/NCT00589563 |
Completed |
City of Hope Medical Center |
2012-02-29 |
| NCT00572897 |
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00572897 |
Completed |
Icahn School of Medicine at Mount Sinai |
2011-08-31 |
| NCT00572065 |
Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00572065 |
Completed |
Weill Medical College of Cornell University |
2009-12-31 |
| NCT00569660 |
Ph II Study of Azacitidine in Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00569660 |
Completed |
M.D. Anderson Cancer Center |
2008-04-30 |
| NCT00509899 |
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00509899 |
Completed |
Incyte Corporation |
2007-12-31 |
| NCT00506402 |
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00506402 |
Completed |
CASI Pharmaceuticals, Inc. |
2009-01-31 |
| NCT00494585 |
CEP-701 for PH-negative Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00494585 |
Completed |
M.D. Anderson Cancer Center |
2010-05-31 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00475020 |
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT00475020 |
Completed |
M.D. Anderson Cancer Center |
2017-10-04 |
| NCT00463385 |
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia |
https://ClinicalTrials.gov/show/NCT00463385 |
Completed |
Celgene |
2009-05-01 |
| NCT00445900 |
Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia |
https://ClinicalTrials.gov/show/NCT00445900 |
Completed |
Mayo Clinic |
2006-10-31 |
| NCT00445744 |
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT00445744 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-06-30 |
| NCT00438958 |
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases |
https://ClinicalTrials.gov/show/NCT00438958 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00424242 |
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases |
https://ClinicalTrials.gov/show/NCT00424242 |
Active, not recruiting |
Northwestern University |
2020-03-31 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00397813 |
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT00397813 |
Completed |
Fred Hutchinson Cancer Research Center |
2017-09-30 |
| NCT00799461 |
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
https://ClinicalTrials.gov/show/NCT00799461 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-11-30 |
| NCT00381550 |
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00381550 |
Completed |
National Cancer Institute (NCI) |
2011-03-31 |
| NCT00360035 |
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia |
https://ClinicalTrials.gov/show/NCT00360035 |
Completed |
Teva Pharmaceutical Industries |
2008-03-31 |
| NCT00357305 |
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT00357305 |
Completed |
National Cancer Institute (NCI) |
2011-11-30 |
| NCT00352794 |
Lenalidomide for Patients With Myelofibrosis (MF) |
https://ClinicalTrials.gov/show/NCT00352794 |
Completed |
M.D. Anderson Cancer Center |
2018-03-08 |
| NCT00351975 |
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases |
https://ClinicalTrials.gov/show/NCT00351975 |
Completed |
National Cancer Institute (NCI) |
2013-03-31 |
| NCT00309842 |
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases |
https://ClinicalTrials.gov/show/NCT00309842 |
Completed |
Masonic Cancer Center, University of Minnesota |
2019-07-29 |
| NCT00287261 |
A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM) |
https://ClinicalTrials.gov/show/NCT00287261 |
Completed |
Universitaire Ziekenhuizen Leuven |
2008-03-31 |
| NCT00274820 |
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder |
https://ClinicalTrials.gov/show/NCT00274820 |
Completed |
Case Comprehensive Cancer Center |
2007-09-30 |
| NCT00255346 |
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) |
https://ClinicalTrials.gov/show/NCT00255346 |
Completed |
M.D. Anderson Cancer Center |
2017-03-03 |
| NCT00235391 |
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload |
https://ClinicalTrials.gov/show/NCT00235391 |
Completed |
Novartis |
2008-10-31 |
| NCT00227591 |
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00227591 |
Completed |
National Cancer Institute (NCI) |
2010-12-31 |
| NCT00136409 |
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) |
https://ClinicalTrials.gov/show/NCT00136409 |
Completed |
Dana-Farber Cancer Institute |
2005-08-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00095784 |
Decitabine in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00095784 |
Active, not recruiting |
National Cancer Institute (NCI) |
2008-07-01 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00088231 |
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP |
https://ClinicalTrials.gov/show/NCT00088231 |
Completed |
M.D. Anderson Cancer Center |
2006-10-31 |
| NCT00087672 |
A Phase II Study of CC-5013 in Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00087672 |
Completed |
M.D. Anderson Cancer Center |
2009-02-28 |
| NCT00086125 |
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) |
https://ClinicalTrials.gov/show/NCT00086125 |
Completed |
Merck Sharp & Dohme Corp. |
2006-06-30 |
| NCT00006367 |
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00006367 |
Completed |
Fred Hutchinson Cancer Research Center |
NA |
| NCT00015821 |
Thalidomide in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00015821 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00047190 |
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia |
https://ClinicalTrials.gov/show/NCT00047190 |
Completed |
National Cancer Institute (NCI) |
2007-04-30 |
| NCT00039416 |
Imatinib Mesylate in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00039416 |
Completed |
National Cancer Institute (NCI) |
2007-08-31 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00081874 |
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00081874 |
Completed |
M.D. Anderson Cancer Center |
2006-09-30 |